Pfizer stock price trades around $28.52 with modest upward momentum. Market watchers note its correlation to pharma ETF performance, underscoring the influence of sector-wide rotation on short-term price action. A looming patent cliff presents another challenge for Pfizer. However, the company has multiple drugs with fast-growing sales that should largely offset any revenue declines from patent expirations. Pfizer's business development deals and pipeline progress should also help boost sales and profits. In other news, Pfizer Inc. (NYSE:PFE) announced on September 30 the signing of a historic agreement with the Trump Administration ensuring that US patients pay lower prices for their prescription medicines while bolstering the country’s role as the global leader in biopharmaceutical innovation. Pfizer stock price trades flat at $28.48, awaiting the Fed’s monetary policy report. Healthcare equities remain in focus as defensive assets amid rate hike uncertainty.